Guest col­umn: The re­al cost of drug de­vel­op­ment

Pun­dits of drug de­vel­op­ment costs use very dif­fer­ent mod­els in com­put­ing the true spend in de­vel­op­ing drugs. At one end of the spec­trum is the phar­ma mod­el: Take all the R&D costs over a decade, and di­vide by the num­ber of drug ap­provals in a sim­i­lar time frame. This gives an in­dus­try av­er­age of over a bil­lion dol­lars per drug and in­cludes the cost of drug fail­ures and re­peat­ed in­di­ca­tions be­fore a suc­cess­ful one is achieved.

Mike Pow­ell

The Tufts Cen­ter for Drug De­vel­op­ment tracks this care­ful­ly, and their re­cent es­ti­mate is $2.6 bil­lion cost per new NME drug. It seems in­cred­i­ble that a phar­ma com­pa­ny may know­ing­ly spend over a bil­lion dol­lars up­front on a sin­gle de­vel­op­ment plan, but by the time the drug hits the ship­ping dock on the way to cus­tomers, this is a fair­ly re­al­is­tic way of ex­press­ing the cost of de­vel­op­ment for that drug.

At the oth­er end of the spec­trum is a pre­dic­tion based on the ac­tu­al costs to con­duct a study with the min­i­mal num­ber of pa­tients for an or­phan in­di­ca­tion. A re­cent study in End­points re­port­ed that the mean piv­otal tri­al cost was $19 mil­lion for a drug ap­proval.

With­out giv­ing away the punch­line, sad­ly, this is some­what akin to claim­ing the re­al cost of dri­ving your car is the cost to fill the gas tank. Or the cost of rais­ing kids is just the food they eat and clothes they wear. In all three cas­es, noth­ing could be fur­ther from the truth.

Ja­son Pitts

Biotech/ven­ture firms al­so have a point of view on the cost for clin­i­cal-stage biotech drug de­vel­op­ment to FDA ap­proval, ie, what do we ac­tu­al­ly spend to take drugs from Phase I through ap­proval. This ap­proach has some con­ve­nient cost sav­ings built in: for ex­am­ple, for aca­d­e­m­ic start-ups, much of the pri­ma­ry re­search cost is borne by NIH and oth­er gov­ern­ment fund­ing, and for phar­ma spin-out com­pa­nies much of the ear­ly work is con­ve­nient­ly tak­en care of by the phar­ma be­fore the biotech com­pa­ny is formed. That leaves just the costs for a clin­i­cal de­vel­op­ment pro­gram from Phase I through FDA ap­proval.

Sim­ple.

Well, hard­ly sim­ple. Sofinno­va, like oth­er ven­ture firms that spe­cial­ize in clin­i­cal-stage drug de­vel­op­ment, has learned through ex­pe­ri­ence what the re­al cost is to push drugs from Phase 1 to FDA ap­proval. Sofinno­va tracks the ‘ful­ly loaded cost of per-pa­tient’ for our com­pa­nies, and has done so for more than a decade. This is ba­si­cal­ly the ful­ly-loaded costs look­ing at what a biotech com­pa­ny spends to dose each pa­tient in­clud­ing the ful­ly loaded costs (GMP man­u­fac­tur­ing, leased space, cost of em­ploy­ees, and oth­er fac­tors).

Tak­ing this ap­proach — and as­sum­ing you can run a biotech com­pa­ny as ef­fi­cient­ly as pos­si­ble — then you take the to­tal spend di­vid­ed by the ac­tu­al num­ber of pa­tients dosed with the drug/place­bo. For ex­am­ple, if a biotech spends $20 mil­lion over 2 years and dos­es 100 pa­tients, the ful­ly loaded cost is $200,000 per pa­tient. This large, ful­ly amor­tized cost per pa­tient num­ber some­times caus­es con­ster­na­tion in the in­dus­try as the di­rect clin­i­cal costs to the CRO are, say, on­ly $5.5 mil­lion, where the re­main­ing $14.5 mil­lion was spent on every­thing else: ba­si­cal­ly the in­fra­struc­ture need­ed to do drug de­vel­op­ment: strong sci­en­tists and clin­i­cians, GMP drug sup­ply, tox­i­col­o­gy stud­ies, and the elec­tric bills that keep the lights on. Va­ca­tion pay, em­ploy­ee bonus and health plans, busi­ness trav­el, IPO and fundrais­ing costs.

If they are do­ing things right, toss in the De­cem­ber hol­i­day par­ty, and jour­nal club costs. It is these ful­ly amor­tized costs that add up quick­ly.

We first com­put­ed the ful­ly loaded cost per pa­tient math cir­ca 2005. As our own biotech port­fo­lio was still grow­ing, we in­for­mal­ly so­licit­ed da­ta from dozens of clin­i­cal com­pa­nies fund­ed by brand name ven­ture firms, in­clud­ing sev­er­al brand-name, Sand Hill Rd firms, and com­bined them to make a con­fi­den­tial dataset of sev­er­al dozen, clin­i­cal­ly ma­ture com­pa­nies, yield­ing the fol­low­ing com­piled da­ta:

Av­er­age com­pa­ny spend = $78 mil­lion

Av­er­age num­ber of pa­tients = 402 (geo­met­ric mean av­er­age)

Av­er­age per pa­tient cost = $168,000.

We felt this was shock­ing­ly high. When we ex­am­ined on­col­o­gy com­pa­nies on­ly, the av­er­age cost per pa­tient was even high­er, $258,000, and for pro­tein ther­a­peu­tic com­pa­nies it was $345,000 per pa­tient.

Al­though this sub­set of biotech com­pa­nies was lim­it­ed at the time, the mes­sage was un­mis­tak­able: The cost to run a ven­ture-backed, clin­i­cal stage biotech for a few years, dos­ing hun­dreds of pa­tients (which is typ­i­cal­ly a very ag­gres­sive num­ber re­quired for FDA ap­proval) is cer­tain­ly not $19 mil­lion.

In the last decade, we have had 17 FDA drug ap­provals come out of Sofinno­va-fund­ed com­pa­nies. Three of these com­pa­nies were ac­quired be­fore FDA ap­proval, and so we don’t have full in­sight in­to the to­tal cost of de­vel­op­ment for these com­pa­nies.

Nonethe­less, the re­main­ing 14 com­pa­nies that took their drugs all the way to FDA ap­proval col­lec­tive­ly raised/spent $4.65 bil­lion, giv­ing an av­er­age cost per drug to ap­proval of $327 mil­lion (+/-264 mil­lion, SD).

Ven­ture-backed biotech com­pa­nies are fair­ly ef­fi­cient at de­vel­op­ing drugs, and we be­lieve this is part of the rea­son why the biotech in­dus­try has boomed for more than two decades.

Bot­tom line: Drug de­vel­op­ment is an ex­pen­sive busi­ness, but those that can do it more ef­fi­cient­ly and cheap­ly than oth­ers should be able to stay in busi­ness.

So why do we do it? Why do we spend so much on de­vel­op­ing drugs, and in­vest­ing in the qual­i­ty of life, for our­selves and our chil­dren? Many things in life are more ex­pen­sive than they might seem on face val­ue, in­clud­ing the car you dri­ve, the chil­dren you raise, and the life-sav­ing drugs you take. Yet all pro­vide a quan­tum change in qual­i­ty of life, de­spite the oc­ca­sion­al flat tire, the di­a­pers and cost of col­lege and, yes, the cost to demon­strate drug ef­fi­ca­cy and safe­ty, held to one of the high­est stan­dards imag­in­able: FDA ap­proval.


Mike Pow­ell is a gen­er­al part­ner and Ja­son Pitts is an as­so­ciate at Sofinno­va Ven­tures.
Im­age: SHUT­TER­STOCK

Cell and Gene Con­tract Man­u­fac­tur­ers Must Em­brace Dig­i­ti­za­tion

The Cell and Gene Industry is growing at a staggering 30% CAGR and is estimated to reach $14B by 20251. A number of cell, gene and stem cell therapy sponsors currently have novel drug substances and products and many rely on Contract Development Manufacturing Organizations (CDMO) to produce them with adherence to stringent regulatory cGMP conditions. Cell and gene manufacturing for both autologous (one to one) and allogenic (one to many) treatments face difficult issues such as: a complex supply chain, variability on patient and cellular level, cell expansion count and a tight scheduling of lot disposition process. This complexity affects quality, compliance and accountability in the entire vein-to-vein process for critically ill patients.

A lab technician works during research on coronavirus at Johnson & Johnson subsidiary Janssen Pharmaceutical in Beerse, Belgium, Wednesday, June 17, 2020. (Virginia Mayo/AP Images)

End­points News ranks all 28 play­ers in the Covid-19 vac­cine race. Here's how it stacks up to­day

The 28 players now in or close to the clinical race to get a Covid-19 vaccine over the finish line are angling for a piece of a multibillion-dollar market. And being first — or among the leaders — will play a big role in determining just how big a piece.

Endpoints News writer Nicole DeFeudis has posted a snapshot of all the companies, universities and hospital-based groups now racing through the clinic, ranking them according to their place in the pipeline as well as the latest remarks available on timelines. And we’ll keep this lineup updated right through the end of the year, as the checkered flags start to fall, possibly as early as October.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,200+ biopharma pros reading Endpoints daily — and it's free.

Phase III read­outs spell dis­as­ter for Genen­tech’s lead IBD drug

Roche had big plans for etrolizumab. Eyeing a hyper-competitive IBD and Crohn’s market where they have not historically been a player, the company rolled out 8 different Phase III trials, testing the antibody for two different uses across a range of different patient groups.

On Monday, Roche released results for 4 of those studies, and they mark a decided setback for both the Swiss pharma and their biotech sub Genentech, potentially spelling an end to a drug they put over half-a-decade and millions of dollars behind.

Bayer's Marianne De Backer with Endpoints founder John Carroll, Endpoints@JPM20 (Jeff Rumans for Endpoints News)

UP­DAT­ED: Hunt­ing a block­buster, Bay­er forges an $875M-plus M&A deal to ac­quire women’s health biotech

Bayer has dropped $425 million in cash on its latest women’s health bet, bringing a UK biotech and its non-hormonal menopause treatment into the fold.

KaNDy Therapeutics had its roots in GlaxoSmithKline, which spun out several neuroscience drugs into NeRRe Therapeutics back in 2012. Five years later the team created a new biotech to focus solely on NT-814 — which they considered “one of the few true innovations in women’s health in more than two decades.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,200+ biopharma pros reading Endpoints daily — and it's free.

Eisai moves to 200 Metro Blvd. by late 2021 (ON3)

Ei­sai is cre­at­ing a new US cor­po­rate, R&D HQ in Roche’s old Nut­ley, NJ cam­pus

Eight years after Roche pulled up stakes from Nutley, NJ in a major R&D reorganization, Japan’s Eisai is moving its US corporate and research hub into their old campus.

Now the ON3 property, Eisai — a longtime Biogen partner focused on neurodegenerative disorders like Alzheimer’s — will bring together a staff of up to 1,200 employees. And execs are pitching the move to the New Jersey campus as a cultural game-changer.

DFC CEO Adam Boehler and Kodak CEO Jim Continenza (Kodak)

Covid-19 roundup: Cure­Vac beefs up its uni­corn IPO dreams as bil­lion­aire own­er takes this Covid-19 mR­NA play­er on a forced march to Nas­daq; Ko­dak's $765M deal is put on hold

When CureVac initially jotted down $100 million for its IPO raise a couple of weeks ago, it seemed small. The German mRNA player, after all, had jumped into a Covid-19 race that swelled the sails of Moderna and BioNTech by tens of billions. And after raising $640 million in a slate of deals, $100 million in a hot market like this seemed like a pittance in the bigger scheme of things.

Today, we got a look at a figure that probably comes closer to the game-changing number the top execs probably have in mind. Selling 15.3 million shares at the high end of their $14 to $16 range would net a $243 million bounty. Majority owner Dietmar Hopp is putting in another €100 million, bringing the total to around $350 million. And what are the chances they want to do even better than that?

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,200+ biopharma pros reading Endpoints daily — and it's free.

Eric Shaff (Seres)

UP­DAT­ED: Af­ter a 4-year so­journ, strug­gling mi­cro­bio­me pi­o­neer Seres claims a break­out PhI­II come­back. And shares re­spond in fren­zied spike

Almost exactly 4 years ago, Seres Therapeutics $MCRB experienced one of those soul-crunching failures that can raise big questions about a biotech’s future. Out front in their pursuit of a gut punch to C. difficile infection (CDI), the Phase II test was a flat failure, and investors wiped out a billion dollars of equity value that never returned in the years that followed.

Seres, though, pressed ahead, changing out CEOs a year ago — bidding Merck vet Roger Pomerantz farewell from the C suite — and pushing through a Phase III, hoping that amping up the dosage would make the key difference. And this morning, they unveiled a claim that they had aced the Phase III and positioned themselves for a run at a landmark FDA OK.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,200+ biopharma pros reading Endpoints daily — and it's free.

Michel Vounatsos, Biogen CEO (via YouTube)

Bio­gen scores a pri­or­i­ty re­view for its Alzheimer's drug ad­u­canum­ab, mov­ing one gi­ant leap for­ward in its con­tro­ver­sial quest

Biogen scored a big win at the FDA today as regulators accepted their application for the controversial Alzheimer’s drug aducanumab and gave it a priority review.

The PDUFA date is March 7, 2021.

Significantly, Biogen says it did not use its priority review voucher to win special treatment at the FDA. The agency handed that out gratis.

That’s the ideal scenario Biogen was looking for as disappointed analysts wondered aloud about the delayed application earlier in the year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,200+ biopharma pros reading Endpoints daily — and it's free.

Robert Gould, Fulcrum Therapeutics CEO

Ful­crum stum­bles in PhII of old GSK drug, send­ing shares tum­bling

Investors are selling off shares of Fulcrum Therapeutics $FULC after their lead drug failed in a Phase II trial.

The company, founded three years ago on new research techniques such as CRISPR screening, isolated a gene called DUX4 they believed to have a central role in facioscapulohumeral muscular dystrophy, where patients’ muscle dies and is replaced by fat. And to target it, they licensed a GlaxoSmithKline drug that had failed as a cardio drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,200+ biopharma pros reading Endpoints daily — and it's free.